Incyte Corporation INCY
123.20
(1.62)
(1.30%)
as of 29 Sep
- Market cap
- $26.1B
- P/E
- 15.4×
Follow INCY
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Incyte Corporation (INCY) Total debt
Incyte Corporation's total debt at the end of fiscal 2025 was $30.2M, down 9.97% from $33.5M in fiscal 2024. At the end of the quarter to 30 June 2026 it was $28.4M. Over the past ten years it has ranged from $17.4M (fiscal 2018) to $651.5M (fiscal 2016); the current reading is higher than 36% of that period. Incyte Corporation ranks 175th of 590 Biotechnology companies by total debt.
Total debt, annual
Annual
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $30.2M | (9.97%) |
| FY2024 | $33.5M | 15.02% |
| FY2023 | $29.2M | (29.02%) |
| FY2022 | $41.1M | (7.95%) |
| FY2021 | $44.6M | (6.18%) |
| FY2020 | $47.6M | (5.27%) |
| FY2019 | $50.2M | 188.05% |
| FY2018 | $17.4M | (27.36%) |
| FY2017 | $24.0M | (96.32%) |
| FY2016 | $651.5M | 5.10% |
Quarterly
| Period | Total debt | Change |
|---|---|---|
| Jun 2026 | $28.4M | (3.38%) |
| Mar 2026 | $29.4M | (2.60%) |
| Dec 2025 | $30.2M | (2.21%) |
| Sep 2025 | $30.9M | (2.77%) |
| 42 more quarters | Free account |
Against its own ten years
Low $17.4M
High $651.5M
Ten-year median
$41.1M
Current reading's percentile
36
Total debt against peers
| Company | Total debt |
|---|---|
| RPRX Royalty Pharma PLC compare | $9.0B |
| GMAB Genmab A/S Sponsored ADR compare | $5.1B |
| JAZZ Jazz Pharmaceuticals PLC compare | $4.4B |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $1.0B |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $882.2M |
| INSM Insmed, Inc. compare | $562.4M |
| BNTX BioNTech SE Sponsored ADR compare | $367.5M |
| ROIV Roivant Sciences Ltd. compare | $323.7M |
| INCY Incyte Corporation | $28.4M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on INCY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement